ChristyLynnOsgoodMD

PubMed

• 18 citations
  US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Ca...
  Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist, William F Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Shenghui Ta...> ;Journal of Clinical Oncology. 2023 Apr 10
• 8 citations
  FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
  Mirat Shah, Christy L Osgood, Anup K Amatya, Mallorie H Fiero, William F Pierce, Abhilasha Nair, Jonathan Herz, Kim J Robertson, Bronwyn D Mixter, Shenghui Tang, Richa...> ;Clinical Cancer Research. 2022 Dec 15
• 2 citations
  Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration.
  Kathleen M Sullivan, Graça M Dores, Afrouz Nayernama, Tatiana M Prowell, Shan M Pradhan, Christy Osgood, S Christopher Jones> ;JAMA Oncology. 2022 Oct 1
• 17 citations
  FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
  Melanie Royce, Christy L Osgood, Anup K Amatya, Mallorie H Fiero, C J George Chang, Tiffany K Ricks, Krithika A Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosan...> ;Clinical Cancer Research. 2022 Apr 14
• 31 citations
  FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
  Melanie Royce, Christy Osgood, Flora Mulkey, Erik Bloomquist, William F Pierce, Arpita Roy, Shyam Kalavar, Reena Philip, Fatima Rizvi, Bronwyn D Mixter, Shenghui Tang,...> ;Journal of Clinical Oncology. 2022 Apr 10
• 25 citations
  U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
  , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Oct 28
• 4 citations
  U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
  , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Oct 28
• 31 citations
  Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor p...
  Jennifer J Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, Danielle Krol, Christy L. Osgood, Gwynn Ison, Rajeshwari...> ;The Lancet. Oncology. 2021 Oct 14
• 19 citations
  FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
  , , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Apr 15
• 48 citations
  FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
  Preeti Narayan, Christy L. Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin Chiu Yuen Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, Frances Namuswe, Maria G...> ;Clinical Cancer Research. 2021 Jan 1
• 28 citations
  FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
  Christy L. Osgood, Meredith K. Chuk, Marc R. Theoret, Lan Huang, Kun He, Leah Her, Patricia Keegan, Richard Pazdur> ;Clinical Cancer Research. 2017 Nov 1
• 10 citations
  18 F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma
  Christy L. Osgood, Mohammed N. Tantawy, Nichole Maloney, Zachary Madaj, Anderson Peck, Elissa Boguslawski, Jennifer Jess, Jason R. Buck, Mary E. Winn, H. Charles Manni...> ;Scientific Reports. 2016 Sep 27
• 48 citations
  Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor
  Christy L. Osgood, Nichole Maloney, Christopher G. Kidd, Susan M. Kitchen-Goosen, Laura E. Segars, Meti Gebregiorgis, Girma M. Woldemichael, Min He, Savita Sankar, Ste...> ;Clinical Cancer Research. 2016 Aug 15
• 9 citations
  Clostridium difficile infection in the pediatric transplant patient.
  Maribeth R. Nicholson, Christy L. Osgood, Sari Acra, Kathryn M. Edwards> ;Pediatric Transplantation. 2015 Nov 1
• Join now to see all

Journal Articles

• Clostridium difficile infection in the pediatric transplant patient  
  Nicholson MR, Osgood CL, Acra SA, Edwards KM, Pediatric Transplantation, 1/1/2015

Abstracts/Posters

• Identification of mithramycin analogs with improved targeting of the EWS/FLI1 transcription factor
  Osgood CL, Maloney KN, Kidd CG, Gebregiorgis M, Woldemichale G, Nunez LE, Morís F, Helman LJ, Grohar PJ, AACR Annual Meeting, 1/1/2015
• Development of an imaging based pharmacodynamic marker of EWS/FLI1 activity for Ewing sarcoma
  Osgood CL, Buck JR, Kwangho K, Sulikowski G, Manning HC, Grohar PJ, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/1/2014
• Development of pharmacodynamic marker of EWS-FLI1 transcription factor blockade in Ewing sarcoma
  Osgood CL, Rose KL, Schey KL, Grohar PJ, Department of Pediatric Annual Research Retreat, Nashville, TN, 1/1/2013
• Emergency physicians miss treatable symptoms in active cancer
  Kennedy CL, Lucey ML, Quest TE, Acad Emerg Med, 1/1/2007
• Achieving EVR in post-liver transplant patients with chronic hepatitis C: is it a fair goal of therapy?
  Kennedy CL, McClure M, Brackett T, Fernandes B, Steinberg T, Kugelmas ME, AM J Transplant, 1/1/2004
• Preliminary results for quantitative liver function tests for patients in the HALT-C trial
  Osgood CL, American Association for the Study of Liver Diseases, Boston, MA, 1/24/2004
• Hepatitis C treatment goals in post liver transplant patients
  Osgood CL, American Transplant Congress, Boston, MA, 1/4./2004
• Emergency physicians miss treatable symptoms in advanced cancer
  Osgood CL, Society for Academic Emergency Medicine Annual Meeting, Chicago, IL, 1/18/2007
• Identification of mithramycin analogs with improved targeting of the EWS/FLI1 transcription factor
  Osgood CL, American Association for Cancer Research Annual Meeting, 1/20/2015
• Development of a pharmacodynamic marker of EWS-FLI1 transcription factor blockade in Ewing sarcoma
  Osgood CL, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/27/2013
• Development of an imaging based pharmacodynamic marker of EWS-FLI1 activity for Ewing sarcoma
  Osgood CL, Vanderbilt University Medical Center, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/17/2014
• Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor
  Osgood CL, Vanderbilt University Medical Center, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/22/2015
• Emergency physicians miss treatable symptoms in advanced cancer
  Osgood CL, Medical Student Research Day, Emory University School of Medicine, Atlanta, GA, 1/24/2006
• Chronic osteomyelitis
  Osgood CL, Pediatrics Residency Educational Conference, Vanderbilt University Medical Center, Nashville, TN, 1/21/2010
• Lymphadenopathy
  Osgood CL, Pediatrics Residency Educational Conference, Vanderbilt University Medical Center, Nashville, TN, 1/10/2010
• Hemolytic anemia
  Osgood CL, Pediatrics Residency Chief’s Case, Vanderbilt University Medical Center, Nashville, TN, 1/2./2012
• Hyperglycemia in induction therapy for acute lymphocytic lymphoma
  Osgood CL, Pediatric Oncology Didactic Conference, Vanderbilt University Medical Center, Nashville, TN, 1/2./2012
• Myeloproliferative disorders
  Osgood CL, Pediatric Oncology Didactic Conference, Vanderbilt University Medical Center, Nashville, TN, 1/1./2012
• Anemia and cancer
  Osgood CL, 3rd year Medical Student Didactic Conference, Meharry Medical College, Nashville, TN, 1/16/2013
• VIP secreting ganglioneuroblastoma
  Osgood CL, Pediatrics Residency Chief’s Case Presentation, Vanderbilt University Medical Center, Nashville, TN, 1/13/2013
• Randomized controlled trial of interval compressed therapy in Ewing sarcoma
  Osgood CL, Vanderbilt University Medical Center Pediatric Oncology Didactic Conference, Nashville, TN, 1/21/2013
• Developmental therapeutics
  Osgood CL, Vanderbilt University Medical Center Hematology/Oncology Fellows Didactic Conference Series, Nashville, TN, 1/28/2014
• Heme-Onc emergencies
  Osgood CL, Pediatric Emergency Medicine Fellow’s Conference, Vanderbilt University Medical Center, 1/17/2014
• Join now to see all

Lectures

• FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019